5Folkman J. Role of angiogenesis in tumor growth and metastasis [J]. Semin Oncol, 2002, 29(16): 15-18.
6Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin [J]. FASEB J, 2001, 15(6):1044-1053.
7Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect [J]. Cancer Res, 2001,61 (2):478-481.
8Hansma AH. A phase I safety and pharmacokinetic(PK) study of continuous intravenous rh-endostatin followed by subcutaneous (s.c.) administration in patients with advanced cancer. Proc ASCO, 2002.
9Eder J P Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily [J]. J Clin Oncol, 2002, 20(18):3772-3784.
10Herbst RS, Hess KR, Tran HT, et al. Phase Ⅰ study of recombinant human endostatin in patients with advanced solid tumors [J]. J Clin Oncol, 2002, 20(18):3792-3803.
3Bradshaw M, Mansfield A, Peikert T. The role of vascularendothelial growth factor in the pathogenesis, diagnosis andtreatment of malignant pleural effusion [J]. Curr Oncol Rep,2013,15(3):207-216.
4Cheng D,Kong H, Li Y. Prognostic values of VEGF and IL-Sin malignant pleural effusion in patients with lung cancer[J].Biomarkers’2013,18(5) :386-390.
5陈碧茵.恶性胸水的治疗现状与进展[J].实用癌症学杂志,2006,21(2):222-223.
6Kim YM, Hwang S,Kim YM,et al. Endostatin blocks vascularendothelial growth factor-mediated signaling via directinteraction with KDR/Flk-l[J]. J Biol Chem,2002,277 (31):27872-27879.
7Ma X, Yao Y, Yuan D, et al. Recombinant human endostatinendostar suppresses angiogenesis and lymphangiogenesis ofmalignant pleural effusion in mice[J], PLoS One.2012,7(12):e53449.
